← Leaderboards
Jennifer M Loftis
Oregon Health And Science University
$3,351,279
Attributed
$6,733,569
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,733,569 · 10
VA$0 · 2
By mechanism
UG3$3,287,052 · 1
R41$1,103,024 · 4
P50$1,011,895 · 1
RC1$944,347 · 1
U18$199,362 · 1
F32$149,772 · 1
Top collaborators
- Marilyn Huckans6 shared
- Kevin Sean Murnane2 shared
- Renee Lynn Shirley2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsAdultAddictionCytokineInflammatoryBlood SpecimenBrainCognitiveNeuropsychiatryBehaviorCognitive FunctionResponseDisease RemissionInflammationImpaired CognitionMethamphetamine DependenceBiologicalTreatment OutcomeImmunePeripheral Blood Mononuclear CellLaboratoriesBaseNeuroimagingAffect
Grant awards (29)
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder$3,287,052
UG3 · FY2025 · DA
Immune-mediated pathogenic mechanisms of Neuro-PASC in Veterans$0
I01 · FY2025 · VA · contact PI
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder$405,334
R41 · FY2024 · DA
Immune-mediated pathogenic mechanisms of Neuro-PASC in Veterans$0
I01 · FY2024 · VA · contact PI
HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function$0
I01 · FY2023 · VA · contact PI
HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function$0
I01 · FY2022 · VA · contact PI
HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function$0
I01 · FY2021 · VA · contact PI
Validation of CD74 as a treatment target for methamphetamine use disorder$199,362
U18 · FY2020 · DA · contact PI
HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function$0
I01 · FY2020 · VA · contact PI
DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder$299,560
R41 · FY2019 · DA · contact PI
HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function$0
I01 · FY2019 · VA · contact PI
Alcohol dependence and HCV: mechanisms of combined CNS injury$0
I01 · FY2017 · VA · contact PI
Traditional Service Core [Translational Service Core (TSC)]$197,952
P50 · FY2016 · DA · contact PI
Alcohol dependence and HCV: mechanisms of combined CNS injury$0
I01 · FY2016 · VA · contact PI
Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction$224,886
R41 · FY2015 · DA · contact PI
Traditional Service Core [Translational Service Core (TSC)]$211,623
P50 · FY2015 · DA · contact PI
Alcohol dependence and HCV: mechanisms of combined CNS injury$0
I01 · FY2015 · VA · contact PI
Traditional Service Core [Translational Service Core (TSC)]$215,814
P50 · FY2014 · DA · contact PI
Alcohol dependence and HCV: mechanisms of combined CNS injury$0
I01 · FY2014 · VA · contact PI
Traditional Service Core [Translational Service Core (TSC)]$191,328
P50 · FY2013 · DA · contact PI
Traditional Service Core [Translational Service Core (TSC)]$195,178
P50 · FY2012 · DA · contact PI
Pre-clinical testing of a novel immunotherapy [recombinant T cell receptor ligand$469,568
RC1 · FY2010 · DA · contact PI
Novel RTL treatment to promote brain repair and cognitive recovery following meth$173,244
R41 · FY2010 · DA · contact PI
Pre-clinical testing of a novel immunotherapy [recombinant T cell receptor ligand$474,779
RC1 · FY2009 · DA · contact PI
Biochemical and Behavioral Correlates of IFN Response$52,048
F32 · FY2007 · MH · contact PI
Biochemical and Behavioral Correlates of IFN Response$50,428
F32 · FY2006 · MH · contact PI
Biochemical and Behavioral Correlates of IFN Response$47,296
F32 · FY2004 · MH
COCAINE EFFECTS ON NMDA RECEPTOR/PROTEIN INTERACTIONS$14,548
F31 · FY2001 · DA
COCAINE EFFECTS ON NMDA RECEPTOR/PROTEIN INTERACTIONS$23,569
F31 · FY2000 · DA